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Abstract
Falls are a major public health concern in the older population, and certain medication classes are a significant risk factor 
for falls. However, knowledge is lacking among both physicians and older people, including caregivers, concerning the role 
of medication as a risk factor. In the present statement, the European Geriatric Medicine Society (EuGMS) Task and Finish 
group on fall-risk-increasing drugs (FRIDs), in collaboration with the EuGMS Special Interest group on Pharmacology and 
the European Union of Medical Specialists (UEMS) Geriatric Medicine Section, outlines its position regarding knowledge 
dissemination on medication-related falls in older people across Europe. The EuGMS Task and Finish group is developing 
educational materials to facilitate knowledge dissemination for healthcare professionals and older people. In addition, steps 
in primary prevention through judicious prescribing, deprescribing of FRIDs (withdrawal and dose reduction), and gaps in 
current research are outlined in this position paper.
Key Points 
Falls are under-recognized as adverse drug events.
Healthcare professionals are reluctant to withdraw fall-
risk-increasing medications.
The EuGMS Task and Finish group on fall-risk-increas-
ing drugs (FRIDs) proposes in this paper its recommen-
dations on dissemination of knowledge about, manage-
ment of, and future research on FRIDs.
1 Introduction
Falls in older people are a significant public health priority 
because of their high prevalence, related injuries, reduced 
quality of life for fallers, and the associated economic burden 
[1]. One-third of people aged ≥65 years fall at least once 
yearly, and 20% of these falls lead to severe injuries [2]. 
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Among older people, approximately 40,000 fatal falls are 
reported in the EU annually [3]. Between 0.85 and 1.50% of 
the total healthcare expenditure in Europe, North America, 
and Australia [4] are fall-related costs, meaning these inju-
ries are among the 20 most expensive medical conditions 
among community-dwelling older people [5]. Medications 
are crucial risk factors for falls, and withdrawal of fall-
risk-increasing drugs (FRIDs) is an effective intervention 
to prevent falls [6]. Moreover, falls, widely acknowledged 
as a geriatric syndrome, are also established adverse drug 
events (ADEs). It is estimated that ADEs lead to 8.6 million 
unplanned hospital admissions in Europe annually, and 50% 
of these are preventable [7]. A total of 70% of ADEs affect 
patients aged > 65 years taking five or more medicines [7].
Despite the evidence of the association between medi-
cations and falls, awareness of this topic is lacking among 
physicians and older people and their caregivers [8–11]. 
Indeed, physicians and patients commonly overestimate 
the benefits of medications and underestimate the poten-
tial harms [12]. Furthermore, many physicians perceive the 
uncertainty about the consequences of withdrawing FRIDs 
as challenging and uncomfortable [9]. Older patients also 
have concerns about deprescribing, such as fearing a relapse 
of their condition, and concerns about adverse drug with-
drawal reactions [13, 14]. Consequently, limited knowledge 
and skills in FRIDs withdrawal and reluctance to withdraw 
mean avoidable injurious events and other adverse outcomes 
related to falls continue.
In this position statement, the European Geriatric Medi-
cine Society (EuGMS) Task and Finish group on FRIDs, 
in collaboration with the EuGMS Special Interest Group 
on Pharmacology and the European Union of Medical Spe-
cialists (UEMS)-Geriatric Medicine Section, outline (1) the 
preferential strategies for knowledge dissemination to older 
people and professionals on FRIDs, (2) recommendations 
for the management of FRIDs, and (3) recommendations for 
future research on medication-related falls.
2  Prevention of Medication‑Related Falls
Psychotropic and cardiovascular medicines are the most 
important FRID classes. The recent systematic reviews 
and meta-analyses by the EuGMS Task and Finish group 
on FRIDs confirmed the association between psychotrop-
ics (antidepressants [selective serotonin reuptake inhibitors, 
tricyclic antidepressants], antipsychotics, benzodiazepines) 
and fall risk [15]. Moreover, consistent associations with 
falls were reported for loop diuretics, antiepileptics, opioids, 
and polypharmacy (four or more medications) [16, 17]. Dig-
italis, non-selective beta-blocking agents, antiarrhythmics, 
diuretics in general, antihypertensives, anticholinergics, 
non-steroidal anti-inflammatory drugs, analgesics, laxatives, 
long-term proton pump inhibitors, and antiplatelets are also 
possible FRIDs [16, 17]. These high-risk medications are 
widely prescribed for older people. Almost 90% of older 
adults with dizziness visiting their general practitioner use 
at least one FRID [18]. Approximately 60% of older adults 
admitted to hospital because of a fall use one or more FRID, 
and 36% use five or more medications [19].
Preventing fall incidents by identifying and reducing 
the use of risk-increasing medications is an essential and 
effective component of a multifactorial fall-risk-manage-
ment approach. A Cochrane review in 2012 summarized 
the randomized controlled trials (RCTs) of interventions 
to reduce falls in community-dwelling older people [6]. 
Gillespie et al. reported that withdrawal of psychotropics is 
effective in reducing fall rates and that a prescribing-mod-
ification program for primary care physicians can reduce 
the risk of falling in older people [6]. In addition, applying 
the FORTA (Fit fOR The Aged) list, a positive–negative 
medication-optimization approach, was effective in reduc-
ing fall rates in hospitalized geriatric patients [20]. Further-
more, the implementation of STOPP/START (Screening 
Tool for Older People’s potentially inappropriate Prescrip-
tions/Screening Tool to Alert doctors to Right Treatment) 
criteria significantly reduced the number of falls in a chronic 
care geriatric facility [21]. The 2010 American Geriatrics 
Society/British Geriatrics Society joint guideline [22] and 
the World Health Organization (WHO) Integrated Care for 
Older People guideline [23] recommend that individuals 
at high risk of falling, identified by screening, should be 
assessed for risk factors, including medication. The medica-
tion review should include an assessment of drug duplicates 
and drug–drug interactions. The American Geriatrics Soci-
ety/British Geriatrics Society joint guideline further states 
that minimizing medications is an important component of 
the multifactorial intervention and that, if discontinuation of 
a FRID is not possible, dose reduction should be considered.
Moreover, about 20% of falls result in serious injuries, 
such as fragility fractures and intracranial bleeding, and 
death [2]. Drug-induced osteoporosis is a growing health 
problem, and many commonly prescribed medications 
contribute to significant bone loss and fractures [24]. In 
the overall risk assessment of drugs contributing to falls 
and their serious consequences, the list of drugs known to 
enhance skeletal fragility (e.g., glucocorticoids, antiepi-
leptics, gonadotropin-releasing hormone agonists and aro-
matase inhibitors) or bleeding (e.g., anticoagulants and anti-
platelet therapy) should also be taken into account [25, 26].
Taken together, the EuGMS Task and Finish group on 
FRIDs
1. advocates better recognition of the role of FRIDs in fall 
incidents and the importance of knowledge dissemina-
tion on this topic,
301EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs (FRIDs)
2. advocates better research quality in the future to gain 
improved insight on FRIDs and their effective and safe 
withdrawal measures,
3. recommends systematically checking for a history of 
falls and high risk of falling before prescribing FRIDs,
4. supports and encourages better implementation of the 
2010 American Geriatrics Society/British Geriatrics 
Society joint guideline recommendations into practice, 
including medication review for all patients with an 
acute fall, recurrent falls in the past year, or problems 
with walking or balance,
5. supports the EuGMS Falls and Fracture Special Inter-
est Group recommendation that healthcare professionals 
screen older people, at least annually, for risk of falling 
[27], suggesting, in addition, a medication review for all 
older people every year, and every 6 months if the older 
individual is frail or vulnerable.
3  How to Reduce the Use 
of Fall‑Risk‑Increasing Drugs (FRIDs)?
The first step in reducing the harm caused by FRIDs is to pre-
vent their inappropriate use in the older population. Tools for 
detection of inappropriate prescribing, such as the Medication 
Appropriateness Index [28–30], have been developed to sup-
port a physician’s clinical judgment. It should be noted that 
listing approaches such as START/STOPP or FORTA include 
aspects of fall risk reduction, as FRIDs are mostly highlighted 
as causative factors. Interventional trials have shown that these 
systematic drug-optimization strategies can reduce drug side 
effects [31, 32], including falls [20]. However, no single ideal 
tool exists currently, and the choice of tool may rely on the pur-
pose of use and availability of data [30, 33]. Such a tool should 
be not only well-designed and comprehensive but also practi-
cal to be implemented in everyday clinical practice [30, 33].
When reviewing a patient’s medication lists, withdrawal 
of FRIDs can be performed safely in older people at high risk 
of falls [34]. Withdrawal can involve immediate cessation of 
medication or a stepwise process depending on the medica-
tion to be withdrawn. For medications to be withdrawn in a 
stepwise manner, specific withdrawal guidelines are available 
in national formularies [35]. Examples of medications to be 
stopped gradually are benzodiazepines, opioids, antidepres-
sants, and beta-blockers. The EuGMS Task and Finish group 
on FRIDs proposes the decision tree shown in Fig. 1 for with-
drawal of FRIDs [36, 37].
4  Multidisciplinary Approach
Healthcare professionals other than physicians, such 
as pharmacists, nurses, physiotherapists, occupational 
therapists, and nutritionists, play an important role in a 
multidisciplinary approach to prevention of drug-related 
falls. The American STEADI (Stopping Elderly Accidents, 
Deaths & Injuries) initiative concludes that a pharmacist 
can screen patients to determine fall risk using a standard-
ized protocol, perform a medication review, and recom-
mend vitamin D supplementation when appropriate [38]. 
Pharmacist-led medication improvement programs have 
led to improved medication use and greater discontinua-
tion of high-risk medications [39, 40]. The pharmacist can 
arrange a fall risk assessment with a primary care team if 
the patient is at risk of falling, as identified through screen-
ing. In a thorough medication review, the pharmacist, in 
close collaboration with the multidisciplinary team and 
particularly the physician, can screen for FRIDs, assess 
the patient’s pharmacotherapy management, formulate 
the patient’s medication management plan, and educate 
the patient about fall-prevention strategies and medica-
tion changes [38]. The EuGMS Task and Finish group on 
FRIDs supports the recommendation of the STEADI ini-
tiative to promote greater involvement of a clinical phar-
macist in the medication review process [38]. Similarly, 
nurses are well positioned to recognize a change in an 
older patient’s risk of falling and communicate this to the 
other multiprofessional team members [41, 42]. Nurses 
can drive organizational change toward falls prevention 
through a team approach by considering planning, imple-
menting, and evaluating a falls-prevention program that 
incorporates identification and minimization of FRIDs 
[41, 42].
5  Barriers to Effective Medication 
Withdrawals
Although withdrawal of FRIDs has been reported to be 
effective in reducing fall rates [6], the majority of older 
people do not have their medication checked or changed 
after a recent fall. An American survey found that only 
3.5% of older people had their medication changed after a 
fall [43]. Furthermore, an observational study in primary 
care reported that withdrawal of FRIDs was performed in 
only 11.7% of seniors with a clear indication (dizziness) 
for withdrawal [18].
Lack of knowledge and skills are among the major 
barriers to providers adopting and implementing effec-
tive fall-prevention approaches [44]. These skills are not 
sufficiently acquired during studies. Physician trainees 
perceive difficulties dealing with multimorbidity, atypical 
disease presentations, and polypharmacy [45]. All these 
components are relevant for the recognition of and pos-
sible preventive interventions for medication-related falls.
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For older people, a lack of perception about fall risk is 
a major barrier to patient participation in fall-prevention 
programs [46]. Older people often have an inappropriately 
positive perception of the possible consequences of a fall 
[47]. Moreover, awareness of medication management as 
an important fall-prevention strategy is low among older 
adults [8]. In addition, older people often do not consider 
medications as a possible risk factor for falls and struggle 
to present their medication-related problem to the physi-
cian [9]. Medication use is usually perceived as an una-
voidable necessity [48].
6  Improving Medication Withdrawal: 
Disseminating Knowledge
To overcome the lack of knowledge and skills among phy-
sicians and the poor awareness among older adults, the 
EuGMS Task and Finish group on FRIDs makes the fol-
lowing recommendations.
1. The European Undergraduate Curriculum in Geriatric 
Medicine should be mandatory in the education of all 
medical students. The curriculum states that graduates 
should know the pathophysiology, diagnosis, assess-
ment, management, and preventive strategies for falls 
[49]. In addition, the EuGMS Task and Finish group on 
FRIDs is developing an English-language educational 
Fig. 1  Decision tree for man-
agement of fall-risk-increasing 
drugs (FRIDs)
Identify FRID
(medication review)
Match FRID use to an 
appropriate indication for 
prescribing
Indication does not exist
(anymore): 
stop the FRID and remember to 
check national formulary to identify 
medications that need stepwise 
withdrawal
Indication (still) exists: 
check for safer alternative or 
whether dose reduction or 
change in dosing time and 
interval is possible
Safer alternative is available:
change to that
No safer alternative is available: 
perform a shared decision making with patient 
and possibly another specialist whether still to 
withdraw or perform a dose reduction based on 
disease and adverse event risk and patient’s 
goals
After withdrawal or dose reduction monitor 
for change in symptoms e.g., dizziness, blurred 
vision, and orthostatic hypotension, fall incidents
and other possible negative outcomes such as 
the onset of symptoms for which the medication 
was prescribed
Withdraw the FRID Continue the FRID
Continue with
reduced dose
Continue with 
same dose
303EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs (FRIDs)
video regarding medication-related falls, which will be 
available through the website of the EuGMS Task and 
Finish group on FRIDs.
2. Knowledge should be disseminated among practising 
physicians and other healthcare professionals through 
seminars, brochures, web pages, and apps; by enlisting 
opinion leaders to influence colleagues; and by con-
ducting educational outreach visits [50]. The Task and 
Finish group is developing English-language e-learning 
material about FRIDs and falls. We encourage Euro-
pean countries to adopt and test the material, translating 
where necessary (Table 1).
3. Public awareness and knowledge should be enhanced 
through media attention, educational material for older 
people, brochures, posters, and web pages [50]. Improv-
ing the health literacy of older adults could be a valuable 
intervention to reduce the harms associated with FRIDs 
[51]. For older people, we are designing an English-
language leaflet about FRIDs for public dissemination. 
We encourage European countries to adopt and test the 
material, translating where appropriate (Table 1).
4. A European FRIDs list should be created. The EuGMS 
Task and Finish group plans to develop a FRIDs list to 
be used as a fall-prevention tool.
7  “Gaps” in Current Research
The evidence for medications as risk factors for falls is based 
on observational studies. To date, RCTs have only rarely 
collected falls as adverse events [15–17]. The EuGMS Task 
and Finish group on FRIDs recommends that falls and fall-
related injuries should be actively sought as adverse events 
in RCTs when applying for a license for a new drug to enter 
the market [52]. In addition, we advocate that older peo-
ple, including the “oldest old,” are adequately represented 
in RCTs as they are the primary users of medications [52]. 
Further research is required to establish the lower limit for 
blood-pressure reduction using antihypertensives in frailer 
older adults, after which the harms of falls and other adverse 
events outweigh the cardiovascular benefits.
Most of the published observational studies on medica-
tions as risk factors for falling have several quality issues, 
including accurate medication and falls ascertainment as 
well as problems with confounder variables [15–17]. The 
EuGMS Task and Finish group on FRIDs supports the fol-
lowing items to increase the quality of observational studies 
further [53, 54].
1. Population Studies should be conducted in populations 
with different characteristics to assess whether different 
populations have dissimilar medication-related fall risks. 
The characteristics of the population, such as frailty, 
should be precisely defined.
2. Outcome We support the fall definition and fall ascer-
tainment recommended by The Prevention of Falls 
Network Europe [55]. A fall should be defined as “an 
unexpected event in which the participant comes to rest 
on the ground, floor or lower level,” and falls should be 
recorded prospectively using daily recording.
3. Medication
(a) The studied target medication should be precisely 
defined, preferably using the WHO-recommended 
anatomical therapeutic chemical (ATC) medica-
tion classification system. This will enable clini-
cians and researchers to harmonize datasets, to 
compare results for the same medication between 
different studies, and to summarize evidence 
through systematic reviews and meta-analyses.
(b) As different pharmacological subgroups and 
individual agents in these subgroups might have 
different fall-risk-increasing properties, these 
subgroups and chemical substances should be 
assessed in future studies.
(c) Collecting data on medication use only at baseline 
in studies makes it likely that medication use by 
participants may change during follow-up. The 
aim should be to perform the medication (ATC 
code, dosage, duration of use) data collection, 
including over-the-counter medications, at a rel-
evant time interval for the fall to minimize bias in 
the studies.
(d) To date, the Drug Burden Index, which evaluates 
the cumulative burden of sedatives and anticholin-
ergics, and different measures of anticholinergic 
Table 1  Steps in translating educational material
EuGMS European Geriatric Medicine Society, FRIDs fall-risk-increasing drugs
1. Check the EuGMS Task and Finish group on FRIDs webpage (http://www.eugms .org/resea rch-coope ratio n/speci al-inter est-group s/falls -and-
fract ures.html) to see whether the educational material is available in your language
2. If not available in your language: The recommended way of translating the material is to use two translators, then conduct a pilot test among 
older adults, correct the translation, test again with older adults and then perform a reverse translation to confirm that the final version is con-
sistent with the original version
3. If you perform a translation, contact us so we may make the material publically available through the EuGMS website
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burden have been associated with increased fall 
risk [16]. However, whether dosage is an impor-
tant factor in falls caused by other medication 
groups should be evaluated in the future. In addi-
tion, investigation of whether fall risks increase 
after initiation of therapy compared with chronic 
use is warranted.
(e) If falls are evaluated as adverse events in observa-
tional studies, then validated criteria such as that 
of the WHO-Uppsala Monitoring Centre (UMC) 
and a rigorous assessment process for rating the 
causality of the event should be used [56, 57].
4. Confounding factors Confounders should be carefully 
chosen. Besides the typical confounders such as comor-
bidities, indicators of frailty, and other factors related to 
the fall risk, drug indication, and concurrent medications 
should be taken into account as possible confounding 
variables.
5. Other issues Combination drugs and therapies and drug–
drug interactions and their effect on fall risk have not 
been actively investigated in studies.
8  Conclusion
The EuGMS Task and Finish group on FRIDs advocates 
more attention to dissemination of knowledge regarding 
FRIDs, increased insight, and improved practice, includ-
ing the following:
• encouraging systematic judicious deprescribing by 
including the following steps: recognizing a possible 
indication for the medication, searching for a safer 
alternative, performing shared decision making, and 
monitoring for symptoms after stopping the FRID.
• disseminating knowledge to healthcare workers, health-
care students, and the older population, which could 
enable a more active role for older individuals in shared 
decision making. Medication-related falls should be 
part of the curriculum for all healthcare students.
• creating a European FRIDs list to be used as a fall-
prevention tool.
• increasing knowledge about the risk of falls associated 
with therapeutic classes and individual medications 
through well-designed observational studies and RCTs.
The EuGMS Task and Finish group on FRIDs empha-
sizes that effective knowledge dissemination and improved 
withdrawal of FRIDs, as a result of that knowledge dis-
semination, is likely to reduce the number of fall injuries 
[50, 58].
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